Next-generation characterization of the Cancer Cell Line Encyclopedia

Nature

Volumn 569, Issue 7757, 2019, Pages 503-508

  Ghandi, Mahmoud ^a   Huang, Franklin W ^a,b,m   Jané Valbuena, Judit ^a,b   Kryukov, Gregory V ^a   Lo, Christopher C ^a   McDonald, E Robert ^c   Barretina, Jordi ^c,o   Gelfand, Ellen T ^a   Bielski, Craig M ^a   Li, Haoxin ^a,b   Hu, Kevin ^a   Andreev Drakhlin, Alexander Y ^a   Kim, Jaegil ^a   Hess, Julian M ^a   Haas, Brian J ^a   Aguet, François ^a   Weir, Barbara A ^a   Rothberg, Michael V ^a   Paolella, Brenton R ^a   Lawrence, Michael S ^a,d,e,f   Akbani, Rehan ^g   Lu, Yiling ^g   Tiv, Hong L ^h   Gokhale, Prafulla C ^h   de Weck, Antoine ⁱ   Mansour, Ali Amin ^a   Oh, Coyin ^a   Shih, Juliann ^a   Hadi, Kevin ^j,k   Rosen, Yanay ^a   Bistline, Jonathan ^a   Venkatesan, Kavitha ^c   Reddy, Anupama ^c   Sonkin, Dmitriy ^c,n   Liu, Manway ^c   Lehar, Joseph ^c   Korn, Joshua M ^c   Porter, Dale A ^c   Jones, Michael D ^c   Golji, Javad ^c   Caponigro, Giordano ^c   Taylor, Jordan E ^a   Dunning, Caitlin M ^a   Creech, Amanda L ^a   Warren, Allison C ^a   McFarland, James M ^a   Zamanighomi, Mahdi ^a   Kauffmann, Audrey ⁱ   Stransky, Nicolas ^a   Imielinski, Marcin ^j,k   Maruvka, Yosef E ^a,d   Cherniack, Andrew D ^a,b   Tsherniak, Aviad ^a   Vazquez, Francisca ^a   Jaffe, Jacob D ^a   Lane, Andrew A ^b   Weinstock, David M ^b   Johannessen, Cory M ^a   Morrissey, Michael P ^c   Stegmeier, Frank ^c   Schlegel, Robert ^c   Hahn, William C ^a,b   Getz, Gad ^a,d,e,f   Mills, Gordon B ^g   Boehm, Jesse S ^a   Golub, Todd R ^a,b,l   Garraway, Levi A ^a,b   Sellers, William R ^a,c   more..

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h Belfer Institute for Innovative Cancer Science   (United States)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

^j NEW YORK GENOME CENTER   (United States)

^k WEILL CORNELL MEDICAL COLLEGE   (United States)

^l HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ NATIONAL CANCER INSTITUTE   (United States)

^o GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H3; MICRORNA; SHORT HAIRPIN RNA; ANTINEOPLASTIC AGENT; HISTONE; TUMOR MARKER;

BIOMARKER; CANCER; CELL COMPONENT; DNA; DRUG; GENE EXPRESSION; GENETIC VARIATION; PHENOTYPE; PROTEIN; RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL LINE; CANCER GENETICS; CELL LINEAGE; CONTROLLED STUDY; CRISPR-CAS9 SYSTEM; DNA METHYLATION; DRUG RESPONSE; DRUG SENSITIVITY; ETHNICITY; GENE EXPRESSION; GENE KNOCKDOWN; GENE TARGETING; HISTONE MODIFICATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN MICROARRAY; RNA SPLICING; DRUG RESISTANCE; ETHNIC GROUP; GENE EDITING; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CELL LINE, TUMOR; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; ETHNIC GROUPS; GENE EDITING; HISTONES; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN ARRAY ANALYSIS; RNA SPLICING;

EID: 85065525804     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/s41586-019-1186-3     Document Type: Article

References (65)

1. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603–607 (2012).
2. Li, H. et al. The landscape of cancer cell line metabolism. Nat. Med. 10.1038/s41591-019-0404-8 (2019).
3. Iorio, F. et al. A landscape of pharmacogenomic interactions in cancer. Cell 166, 740–754 (2016).
4. Ben-David, U. et al. Genetic and transcriptional evolution alters cancer cell line drug response. Nature 560, 325–330 (2018).
5. Tsherniak, A. et al. Defining a cancer dependency Map. Cell 170, 564–576 (2017).
6. McDonald, E. R. III et al. Project DRIVE: a compendium of cancer dependencies and synthetic lethal relationships uncovered by large-scale, deep RNAi screening. Cell 170, 577–592 (2017).
7. Meyers, R. M. et al. Computational correction of copy number effect improves specificity of CRISPR–Cas9 essentiality screens in cancer cells. Nat. Genet. 49, 1779–1784 (2017).
8. Huang, F. W. et al. Highly recurrent TERT promoter mutations in human melanoma. Science 339, 957–959 (2013).
9. Diouf, B. et al. Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells. Nat. Med. 17, 1298–1303 (2011).
10. Marra, G. et al. Mismatch repair deficiency associated with overexpression of the MSH3 gene. Proc. Natl Acad. Sci. USA 95, 8568–8573 (1998).
11. Esakova, O. & Krasilnikov, A. S. Of proteins and RNA: the RNase P/MRP family. RNA 16, 1725–1747 (2010).
12. Hands-Taylor, K. L. et al. Heterodimerization of the human RNase P/MRP subunits Rpp20 and Rpp25 is a prerequisite for interaction with the P3 arm of RNase MRP RNA. Nucleic Acids Res. 38, 4052–4066 (2010).
13. Doherty, J. R. & Cleveland, J. L. Targeting lactate metabolism for cancer therapeutics. J. Clin. Invest. 123, 3685–3692 (2013).
14. Herman, J. G. et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl Acad. Sci. USA 91, 9700–9704 (1994).
15. Jaffe, J. D. et al. Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. Nat. Genet. 45, 1386–1391 (2013).
16. Creech, A. L. et al. Building the Connectivity Map of epigenetics: chromatin profiling by quantitative targeted mass spectrometry. Methods 72, 57–64 (2015).
17. Sveen, A., Kilpinen, S., Ruusulehto, A., Lothe, R. A. & Skotheim, R. I. Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes. Oncogene 35, 2413–2427 (2016).
18. Dewaele, M. et al. Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth. J. Clin. Invest. 126, 68–84 (2016).
19. Rallapalli, R., Strachan, G., Cho, B., Mercer, W. E. & Hall, D. J. A novel MDMX transcript expressed in a variety of transformed cell lines encodes a truncated protein with potent p53 repressive activity. J. Biol. Chem. 274, 8299–8308 (1999).
20. Gembarska, A. et al. MDM4 is a key therapeutic target in cutaneous melanoma. Nat. Med. 18, 1239–1247 (2012).
21. Boutz, P. L., Bhutkar, A. & Sharp, P. A. Detained introns are a novel, widespread class of post-transcriptionally spliced introns. Genes Dev. 29, 63–80 (2015).
22. Maruvka, Y. E. et al. Analysis of somatic microsatellite indels identifies driver events in human tumors. Nat. Biotechnol. 35, 951–959 (2017).
23. Zhang, Y. et al. Ribosomal proteins Rpl22 and Rpl22l1 control morphogenesis by regulating pre-mRNA splicing. Cell Reports 18, 545–556 (2017).
24. Lu, J. et al. MicroRNA expression profiles classify human cancers. Nature 435, 834–838 (2005).
25. Li, J. et al. Characterization of human cancer cell lines by reverse-phase protein arrays. Cancer Cell 31, 225–239 (2017).
26. Chen, Y. N. et al. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature 535, 148–152 (2016).
27. Wylie, A. A. et al. The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1. Nature 543, 733–737 (2017).
28. Haibe-Kains, B. et al. Inconsistency in large pharmacogenomic studies. Nature 504, 389–393 (2013).
29. The Cancer Cell Line Encyclopedia Consortium & The Genomics of Drug Sensitivity in Cancer Consortium. Pharmacogenomic agreement between two cancer cell line datasets. Nature 528, 84–87 (2015).
30. Haverty, P. M. et al. Reproducible pharmacogenomic profiling of cancer cell line panels. Nature 533, 333–337 (2016).
31. Geeleher, P., Gamazon, E. R., Seoighe, C., Cox, N. J. & Huang, R. S. Consistency in large pharmacogenomic studies. Nature 540, E1–E2 (2016).
32. Bouhaddou, M. et al. Drug response consistency in CCLE and CGP. Nature 540, E9–E10 (2016).
33. Mpindi, J. P. et al. Consistency in drug response profiling. Nature 540, E5–E6 (2016).
34. Yu, C. et al. High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines. Nat. Biotechnol. 34, 419–423 (2016).
35. King, A. J. et al. Abstract 2116: Combining the power of different profiling approaches to better understand the activity of kinase inhibitor drugs. Cancer Res. 77, 2116–2116 (2017).
36. Fisher, S. et al. A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries. Genome Biol. 12, R1 (2011).
37. Johannessen, C. M. et al. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature 504, 138–142 (2013).
38. Boyle, P. et al. Gel-free multiplexed reduced representation bisulfite sequencing for large-scale DNA methylation profiling. Genome Biol. 13, R92 (2012).
39. Brat, D. J. et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N. Engl. J. Med. 372, 2481–2498 (2015).
40. Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 159, 676–690 (2014).
41. Huang, F. W. et al. TERT promoter mutations and monoallelic activation of TERT in cancer. Oncogenesis 4, e176 (2015).
42. Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213–219 (2013).
43. Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285–291 (2016).
44. Van der Auwera, G. A. et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr. Protoc. Bioinformatics 43, 11.10.11–11.10.33 (2013).
45. Wala, J. A. et al. SvABA: genome-wide detection of structural variants and indels by local assembly. Genome Res. 28, 581–591 (2018).
46. Haas, B. et al. STAR-Fusion: fast and accurate fusion transcript detection from RNA-seq. Preprint at https://www.bioRxiv.org/content/10.1101/120295v1 (2017).
47. Kasar, S. et al. Whole-genome sequencing reveals activation-induced cytidine deaminase signatures during indolent chronic lymphocytic leukaemia evolution. Nat. Commun. 6, 8866 (2015).
48. Kim, J. et al. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat. Genet. 48, 600–606 (2016).
49. The Cancer Genome Atlas Research Network. Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell 171, 950–965 (2017).
50. Haradhvala, N. J. et al. Distinct mutational signatures characterize concurrent loss of polymerase proofreading and mismatch repair. Nat. Commun. 9, 1746 (2018).
51. Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413–421 (2012).
52. Krueger, F. & Andrews, S. R. Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications. Bioinformatics 27, 1571–1572 (2011).
53. Akalin, A. et al. methylKit: a comprehensive R package for the analysis of genome-wide DNA methylation profiles. Genome Biol. 13, R87 (2012).
54. Ziller, M. J. et al. Charting a dynamic DNA methylation landscape of the human genome. Nature 500, 477–481 (2013).
55. van der Maaten, L. & Hinton, G. Visualizing high-dimensional data using t-SNE. J. Mach. Learn. Res. 9, 2579–2605 (2008).
56. Szklarczyk, D. et al. STRINGv10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 43, D447–D452 (2015).
57. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2012).
58. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).
59. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
60. DeLuca, D. S. et al. RNA-SeQC: RNA-seq metrics for quality control and process optimization. Bioinformatics 28, 1530–1532 (2012).
61. GTEx Consortium. Genetic effects on gene expression across human tissues. Nature 550, 204–213 (2017).
62. Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).
63. Smyth, G. K. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, 1–25 (2004).
64. Akbani, R. et al. A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat. Commun. 5, 3887 (2014).
65. Friedman, J., Hastie, T. & Tibshirani, R. Regularization paths for generalized linear models via coordinate descent. J. Stat. Softw. 33, 1–22 (2010).